J. Goldman & Co’s Sarepta Therapeutics SRPT Stock Holding History

J. Goldman & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,000	Closed	-$2.5M	–	615
2024 Q3	$2.5M	Buy	+20,000	New	+$2.76M	0.07%	218
2019 Q4	–	Sell	-50,000	Closed	-$3.77M	–	350
2019 Q3	$3.77M	Buy	+50,000	New	+$5.9M	0.28%	105
2018 Q3	–	Sell	-30,000	Closed	-$3.96M	–	381
2018 Q2	$3.96M	Buy	+30,000	New	+$2.83M	0.2%	152
2016 Q3	–	Sell	-156,000	Closed	-$2.98M	–	390
2016 Q2	$2.98M	Buy	+156,000	New	+$2.89M	0.16%	147

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's SRPT Position: Q1 2025 in Review

J. Goldman & Co sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 87,866 shares — an estimated $9.25M sold.

J. Goldman & Co first reported a position in SRPT in Q3 2015 and held it in 14 quarters. The position peaked at $12.4M in Q3 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

J. Goldman & Co reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
J. Goldman & Co sold 87,866 Sarepta Therapeutics shares in Q1 2025, an estimated $9.25M.
J. Goldman & Co first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 14 quarters.
J. Goldman & Co's Sarepta Therapeutics position peaked at $12.4M in Q3 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.